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a reliableNonalcoholic fatty liver disease (NAFLD), which deﬁnes alcohol-
like liver histologic changes in nonalcoholic individuals who are
free of any other competing etiologies of liver disease, is a common
disease worldwide [1]. Over the past years, however, it has become
increasingly evident that NAFLD is not merely a liver disease but
also a multisystem condition[2], whose natural course may include
cardiovascular, metabolic, neoplastic or liver-related complications
[3]. Substantial insight has recently been gained into the role of ge-
netic [4,5] and epidemiological risk modiﬁers [6], which may affect
the development and progression of NAFLD. The genetic polymor-
phisms of the patatin-like phospholipase domain containing 3
(PNPLA3) and the trans-membrane 6 superfamily member 2
(TM6SF2) genes have been identiﬁed as the two most relevant ge-
netic modiﬁers of the risk of developing liver-related or extra-
hepatic manifestations of NAFLD [4,5]. A key concept is that so inex-
tricable is the bidirectional relationship between NAFLD and the
metabolic syndrome (MetS) that NAFLDmay occur as either a cause
or a consequence of the MetS [4,7]. However, based on a current
paradigm, individuals who are carriers of the G allele at rs
738409 of the PNPLA3 gene are at increased risk of NAFLD progres-
sion, but they are usually spared from insulin resistance and MetS
traits [4]. If this is the case, it can reasonably be anticipated that,
based on the PNPLA3 genetic variants, at least two distinct forms
of NAFLD do exist: one with and another without MetS and its
inherent cardio-metabolic risk.
Against this complex scenario, the proof-of-concept study pub-
lished in this issue of Atherosclerosis by Di Costanzo et al. [8] further
supports the notion that NAFLD is a heterogeneous and complex
disease and that, stated otherwise, “not all forms of NAFLD were
created equal”, especially with regard to the NAFLD-related car-
dio-metabolic risk. In their case-control study, the authors haved carotid intima-media thickness (CIMT) measurements,
marker of subclinical atherosclerosis [9], in three highly
selected groups of individuals: 83 blood donors with the mutant
PNPLA3 GG genotype (group G; 42.2% of whom had imaging-
diagnosed NAFLD), 100 patients with coexistent NAFLD and MetS,
but with the wild-type PNPLA3 CC genotype (group M), and 74
blood donors with the wild-type PNPLA3 CC genotype (controls;
21.7% of whom had NAFLD). After adjustment for potential con-
founding factors (age, sex, smoking and steatosis severity), the au-
thors found that the median CIMT in group M was signiﬁcantly
higher than that in group G, which was similar to that in the control
group (median CIMT: 0.84 vs. 0.66 vs. 0.70 mm, respectively). Re-
sults remained unchanged even when NAFLD-positive participants
from groups M and G were compared to controls without hepatic
steatosis on ultrasonography [8]. Collectively, these ﬁndings are
compatible with the view that the MetS-related NAFLD and the
PNPLA3-related NAFLD may exert a differential impact on early ca-
rotid atherosclerosis. These data, therefore, support the possibility
that NAFLD is associated with an increased burden of subclinical
atherosclerosis only when it is linked to MetS traits rather than
when it occurs owing to the PNPLA3rs738409 gene polymorphism.
However, as reported in Table 1 [8,10e12], when speciﬁc refer-
ence is made to PNPLA3 gene polymorphisms, data are conﬂicting,
which weakens this general paradigm. The dogma that certain (ge-
netic) forms of NAFLD are typically disconnected from insulin resis-
tance and the MetS should, therefore, be currently accepted more
as an important research question than as a piece of acquired
knowledge. Indeed, growing evidence supports the existence of a
strong association between NAFLD and increased risk of cardio-
metabolic diseases. Several prospective studies have shown that
NAFLD is strongly associated with an increased incidence of type
2 diabetes andMetS [1,2,6,7]. A number of studies have consistently
demonstrated that patients with NAFLD have an excess risk of both
subclinical and clinically manifest cardiovascular disease (CVD)
[2,3,9,13]. In particular, convincing evidence now substantiates a
link between NAFLD and variousmarkers of sub-clinical atheroscle-
rosis (notably including increased CIMT and elevated coronary ar-
tery calciﬁcation score [CAC]), independently of conventional risk
factors and MetS traits, in a wide range of patient populations
[14e16]. Some studies have also shown that NAFLD is associated
with a higher prevalence of carotid atherosclerotic plaques and
greater severity of coronary artery stenosis, independently of mul-
tiple cardio-metabolic risk factors [14]. Interestingly, in a large
cohort study of adults with no history of CVD, NAFLD was associ-
ated with the development of CAC, independent of cardiovascular
Table 1
Principal studies assessing the relationship between the patatin-like phospholipase-3 (PNPLA3) rs738409 gene polymorphism and the risk of atherosclerosis.
Authors, year [ref.] Study
characteristics
NAFLD
diagnosis
Study
outcome(s)
Main
ﬁndings
Petta et al., 2013 [10] South Italy cohort: 162
consecutive patients
with NAFLD; Northern
Italy cohort: 267
patients with NAFLD
Biopsy Carotid intima-media thickness
and plaque on ultrasound
In both study cohorts, the PNPLA3 GG genotype
was independently associated with greater
severity of carotid atherosclerosis in younger
patients with NAFLD (patients <50 years).
In a subgroup of 63 patients, who underwent
ultrasonographic follow-up of carotid assessment,
the PNPLA3 GG genotype was also independently
associated with carotid intima-media thickness
progression over time.
Posadas-Sanchez
et al., 2016 [11]
The Genetics of
Atherosclerotic Disease
study of 1013 Mexican
patients with premature
ischemic heart disease
and 1469 healthy controls
Computed
tomography
Premature ischemic heart
disease (deﬁned as history
of myocardial infarction,
coronary revascularizations
or stenosis >50% on coronary
angiography, diagnosed before
age 55 years in men and before
age 65 years in women).
Coronary calcium score on
computed tomography
The I148M/PNPLA3 polymorphism was not
signiﬁcantly associated with premature
ischemic heart disease in the entire group
of participants. However, when patients and
controls were divided into those with and
without type 2 diabetes, under additive model,
the I148M/PNPLA3 polymorphism was
signiﬁcantly associated with the presence of
premature ischemic heart disease in patients
with type 2 diabetes. Moreover, in the control
group, the I148M/PNPLA3 polymorphism was
independently associated with coronary artery
calciﬁcation score 10.
Xia et al., 2016 [12] Community-based cohort
of 4300 middle-aged and
elderly Chinese individuals
Liver fat content
determined by a
quantitative
ultrasound method
Carotid intima-media
thickness on ultrasound
Compared to the PNPLA3 CC homozygotes,
the GG homozygotes had higher liver fat
and liver ﬁbrosis scores. An increase in liver
fat was accompanied by a signiﬁcant increase
in the average and maximum carotid intima-media
thickness in subjects with the PNPLA3 CC genotype,
but not in those with the GG genotype.
Di Costanzo
et al., 2016 [8]
Three selected groups of
middle-aged Italian
individuals: 74 blood donors
with PNPLA3 CC genotype
(21.7% of whom had NAFLD),
83 blood donors with PNPLA3
GG genotype (group G; 42.2%
had NAFLD) and 100 patients
with coexistent metabolic
syndrome and NAFLD but
with the PNPLA3 CC
genotype (group M)
Ultrasound and
magnetic resonance
(in a subgroup
of 157 subjects)
Carotid intima-media
thickness on ultrasound
Patients with NAFLD and PNPLA3 CC genotype
(group M) had signiﬁcantly greater carotid
intima-media thickness compared to the other
two groups of individuals. In contrast, carotid
intima-media thickness was comparable between
blood donors with PNPLA3 GG genotype and those
with PNPLA3 CC genotype. Results remained
unchanged even when NAFLD-positive
participants from groups M and G were
compared to controls without hepatic
steatosis on ultrasound.
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and meta-analysis of 16 observational studies, involving approxi-
mately 34,000 individuals (36.3% of whomwith NAFLD as detected
by imaging or histology) followed-up over a median period of 6.9
years, has conﬁrmed that patients with NAFLD had a higher risk
of fatal and non-fatal CVD events than those without NAFLD
(random effect odds ratio [OR] 1.64, 95% conﬁdence intervals [CI]
1.3e2.1). Patients with more severe NAFLD were more likely to
develop fatal and non-fatal CVD events (OR 2.58; 95%CI 1.8e3.7)
[18].
On this background of evidence, the results of the study by Di
Costanzo et al. [8] provide further support to the view that the aeti-
ology of NAFLD is multifactorial and this disease may be caused by
common genetic variants. One of these, the PNPLA-3 variant, is
associated with higher liver fat content and increased risk of
NASH, but is not systematically associated with insulin resistance
and MetS traits [4,5]. This study adds a further critical piece of in-
formation by suggesting that the MetS-related NAFLD and the
PNPLA3-related NAFLD may differentially affect the risk of subclin-
ical atherosclerosis and perhaps of clinical CVD [8]. However, it
does not detract from the notion that NAFLD, especially NASH
with varying degrees of ﬁbrosis, may directly contribute to the
development and progression of CVD [2,3,9], because genetic
NAFLD is a subtly different disease and less than 15% of Europeanpatients with NAFLD have the PNPLA3 GG genotype [4,5]. Further-
more, as previously mentioned, the few observational studies
that have assessed the association between the PNPLA3 rs738409
gene polymorphism and risk of atherosclerosis have provided con-
ﬂicting results (as summarized in Table 1) [8,10e12].
That said, the study by Di Costanzo et al. [8] has some important
drawbacks that should be mentioned. Firstly, this study was limited
by its single-center and cross-sectional (case-control) design,
which does not allow drawing any ﬁrm conclusion about the tem-
porality or causality of the observed associations. In addition, the
sample size of the study was relatively small and, although the
multivariate regression models were sufﬁciently adjusted
(including for age that markedly differed among the three groups
of participants), unmeasured confounding factors might potentially
explain the observed associations. Furthermore, the diagnosis of
NAFLDwas based on either ultrasonography or magnetic resonance
imaging/spectroscopy (only in a subgroup of individuals), but was
not conﬁrmed by liver biopsy, which is considered the reference
standard for diagnosing and staging NAFLD. Finally, although the
PNPLA3 GG genotype is the strongest genetic determinant of
NAFLD, the authors did not genotype their study participants for
other genetic variants associated with NAFLD (e.g., the TM6SF2
gene).
Notwithstanding these limitations, the ﬁndings of the study by
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Author's Personal CopyDi Costanzo et al. appear to be biologically plausible. Indeed, other
examples of dissociation of NAFLD due tomolecularly characterized
genetic polymorphisms from cardio-metabolic risk have been pre-
viously described in humans [19]. The intriguing piece of transla-
tional research by Di Costanzo et al. [8] should, accordingly, be
best conﬁrmed in large and well-designed prospective studies.
These studies should take into account the severity of NAFLD histol-
ogy, which is a powerful contributor to the increased cardio-
metabolic risk observed in patients with NAFLD [18]. Furthermore,
all patients with NAFLD should be better genotyped in order to
elucidate the possible differential impact of the PNPLA3 gene and
other genetic variants on liver disease progression and risk of
CVD and other extra-hepatic complications, such as chronic kidney
disease. For instance, preliminary evidence suggests that carriers of
the PNPLA3 GG genotypewith a normal body weight have impaired
kidney function (i.e., an established risk factor for CVD) compared
to those carrying the CC genotype [20].
It is hoped that the results of these future large prospective
studies with sufﬁciently long follow-upwill provide amore tailored
approach to the diagnosis and treatment of patients with NAFLD
based on their individual proﬁle of cardio-metabolic risk [9]. Addi-
tionally, it also hoped that the results of these studies will help to
better elucidate the biological mechanisms dissociating increased
liver fat content from cardio-metabolic complications in selected
patients with NAFLD carrying speciﬁc genetic polymorphisms.
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